Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Keep all medicine out of the reach of children and pets
Pediatr Res 1984;18:815-9
Growth (1980) 44(2):7788
& Lamont, R
However, big pharma will still have the ability to charge premium prices for innovator molecules, especially those with higher efficacy (eg retatrutide) and those aimed at niche patient populations rather than the mass market (eg survodutide, which is targeting MASH endpoints in clinical trials)
US$ 29.68
US$ 28.87
US$ 24.71
US$ 23.37
US$ 28.78
US$ 23.55
